Analyst Price Targets — MGNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 9:24 am | — | Barclays | $6.00 | $3.46 | TheFly | MacroGenics price target raised to $6 from $4 at Barclays |
| May 14, 2025 9:31 am | Peter Lawson | Barclays | $3.00 | $1.59 | TheFly | MacroGenics price target lowered to $3 from $8 at Barclays |
| March 25, 2025 10:05 am | — | H.C. Wainwright | $2.00 | $1.79 | TheFly | MacroGenics price target lowered to $2 from $4 at H.C. Wainwright |
| August 7, 2024 10:18 am | Stephen Willey | Stifel Nicolaus | $6.00 | $3.38 | StreetInsider | MacroGenics (MGNX) PT Lowered to $6 at Stifel |
| July 31, 2024 6:33 am | Silvan Tuerkcan | JMP Securities | $8.00 | $5.25 | TheFly | MacroGenics price target lowered to $8 from $16 at JMP Securities |
| July 31, 2024 3:21 am | Mayank Mamtani | B.Riley Financial | $5.00 | $5.25 | StreetInsider | B.Riley Downgrades MacroGenics (MGNX) to Neutral |
| July 29, 2024 5:41 am | Peter Lawson | Barclays | $9.00 | $5.55 | TheFly | MacroGenics price target lowered to $9 from $14 at Barclays |
| May 23, 2024 6:39 pm | Kaveri Pohlman | BTIG | $9.00 | $4.63 | TheFly | MacroGenics price target lowered to $9 from $24 at BTIG |
| May 13, 2024 7:17 am | Debjit Chattopadhyay | H.C. Wainwright | $4.00 | $4.38 | StreetInsider | MacroGenics (MGNX) PT Lowered to $4 at H.C. Wainwright |
| May 10, 2024 5:23 am | Peter Lawson | Barclays | $14.00 | $14.67 | TheFly | MacroGenics price target lowered to $14 from $25 at Barclays |
Latest News for MGNX
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics' good manufacturing practice (GMP)…
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration's (FDA) accelerated approval of TZIELD® (teplizumab-mzwv) to…
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.
MacroGenics (MGNX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.65 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MGNX.
U.S. House Trading
No House trades found for MGNX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.